Home
>
US Stocks
>
CHINOOK THERAPEUTICS INC

CHINOOK THERAPEUTICS INC (KDNY)

$23.83

+0.52

(+2.23%)▲

Live

Insights on CHINOOK THERAPEUTICS INC

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 512.0K → 1.82M (in $), with an average increase of 72.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -62.55M → -60.17M (in $), with an average increase of 4.0% per quarter

Performance

  • $23.30
    $24.10
    $23.83
    downward going graph

    2.22%

    Downside

    Day's Volatility :3.32%

    Upside

    1.12%

    downward going graph
  • $13.84
    $27.44
    $23.83
    downward going graph

    41.92%

    Downside

    52 Weeks Volatility :49.56%

    Upside

    13.16%

    downward going graph

Returns

PeriodCHINOOK THERAPEUTICS INCSector (Health Care)Index (Russel 2000)
3 Months
6.83%
0.3%
-6.7%
6 Months
2.91%
-8.3%
-6.2%
1 Year
53.56%
-4.8%
-6.3%
3 Years
38.34%
23.8%
26.9%

Highlights

Market Capitalization
1.6B
Book Value
$6.17
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.23
Wall Street Target Price
36.0
Profit Margin
0.0%
Operating Margin TTM
-3843.62%
Return On Assets TTM
-23.5%
Return On Equity TTM
-51.56%
Revenue TTM
5.3M
Revenue Per Share TTM
0.08
Quarterly Revenue Growth YOY
-32.2%
Gross Profit TTM
-135.1M
EBITDA
-197.0M
Diluted Eps TTM
-3.23
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.23
EPS Estimate Next Year
-3.45
EPS Estimate Current Quarter
-0.79
EPS Estimate Next Quarter
-0.81

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for CHINOOK THERAPEUTICS INC(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
17
15
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 51.07%

Current $23.83
Target $36.00

Company Financials

FY19Y/Y Change
Revenue
17.3M
-
Net Income
-82.4M
-
Net Profit Margin
-477.3%
-
FY20Y/Y Change
Revenue
827.0K
↓ 95.21%
Net Income
-81.6M
↓ 0.91%
Net Profit Margin
-9.9K%
↓ 9392.35%
FY21Y/Y Change
Revenue
51.6K
↓ 93.76%
Net Income
-102.9K
↓ 99.87%
Net Profit Margin
-199.39%
↑ 9670.26%
FY22Y/Y Change
Revenue
6.1M
↑ 11770.22%
Net Income
-187.9M
↑ 182404.83%
Net Profit Margin
-3.1K%
↓ 2866.29%
Q4 FY21Q/Q Change
Revenue
-375.4K
↓ 9484.37%
Net Income
110.4M
↓ 459.59%
Net Profit Margin
-29.4K%
↑ 737994.99%
Q1 FY22Q/Q Change
Revenue
2.7M
↓ 818.48%
Net Income
-31.7M
↓ 128.7%
Net Profit Margin
-1.2K%
↑ 28230.22%
Q2 FY22Q/Q Change
Revenue
418.0K
↓ 84.5%
Net Income
-37.6M
↑ 18.82%
Net Profit Margin
-9.0K%
↓ 7831.91%
Q3 FY22Q/Q Change
Revenue
2.5M
↑ 498.33%
Net Income
-56.0M
↑ 48.69%
Net Profit Margin
-2.2K%
↑ 6768.44%
Q4 FY22Q/Q Change
Revenue
512.0K
↓ 79.53%
Net Income
-62.6M
↑ 11.75%
Net Profit Margin
-12.2K%
↓ 9979.32%
Q1 FY23Q/Q Change
Revenue
1.8M
↑ 257.03%
Net Income
-60.2M
↓ 3.8%
Net Profit Margin
-3.3K%
↑ 8925.62%
FY19Y/Y Change
Total Assets
291.3M
-
Total Liabilities
225.7M
-
FY20Y/Y Change
Total Assets
384.5M
↑ 31.98%
Total Liabilities
94.4M
↓ 58.19%
FY21Y/Y Change
Total Assets
563.8M
↑ 46.65%
Total Liabilities
110.2M
↑ 16.72%
FY22Y/Y Change
Total Assets
574.1M
↑ 1.82%
Total Liabilities
132.1M
↑ 19.96%
Q4 FY21Q/Q Change
Total Assets
563.8M
↑ 47.1%
Total Liabilities
110.2M
↓ 2.95%
Q1 FY22Q/Q Change
Total Assets
531.3M
↓ 5.77%
Total Liabilities
104.5M
↓ 5.16%
Q2 FY22Q/Q Change
Total Assets
601.2M
↑ 13.17%
Total Liabilities
94.1M
↓ 9.92%
Q3 FY22Q/Q Change
Total Assets
590.3M
↓ 1.81%
Total Liabilities
115.7M
↑ 22.94%
Q4 FY22Q/Q Change
Total Assets
574.1M
↓ 2.75%
Total Liabilities
132.1M
↑ 14.21%
Q1 FY23Q/Q Change
Total Assets
543.9M
↓ 5.26%
Total Liabilities
131.5M
↓ 0.5%
FY18Y/Y Change
Operating Cash Flow
-6.0K
-
Investing Cash Flow
-758.0K
-
Financing Cash Flow
6.0K
-
FY19Y/Y Change
Operating Cash Flow
-13.6M
↑ 226366.67%
Investing Cash Flow
-758.0K
↑ 0.0%
Financing Cash Flow
25.7M
↑ 428000.0%
FY20Y/Y Change
Operating Cash Flow
-55.8M
↑ 311.01%
Investing Cash Flow
109.7M
↓ 14568.6%
Financing Cash Flow
124.3M
↑ 383.89%
FY21Y/Y Change
Operating Cash Flow
-102.7M
↑ 83.97%
Investing Cash Flow
-112.6M
↓ 202.71%
Financing Cash Flow
209.5M
↑ 68.57%
Q4 FY21Q/Q Change
Operating Cash Flow
-22.5M
↓ 9.01%
Investing Cash Flow
-77.7M
↑ 2769.69%
Financing Cash Flow
173.6M
↑ 66929.34%
Q1 FY22Q/Q Change
Operating Cash Flow
-24.7M
↑ 9.87%
Investing Cash Flow
-55.6M
↓ 28.51%
Financing Cash Flow
1.8M
↓ 98.98%
Q2 FY22Q/Q Change
Operating Cash Flow
-30.6M
↑ 23.85%
Investing Cash Flow
-33.8M
↓ 39.25%
Financing Cash Flow
107.1M
↑ 5977.2%
Q3 FY22Q/Q Change
Operating Cash Flow
-25.3M
↓ 17.33%
Investing Cash Flow
-13.1M
↓ 61.11%
Financing Cash Flow
18.8M
↓ 82.42%
Q1 FY23Q/Q Change
Operating Cash Flow
-50.7M
↑ 37.58%
Investing Cash Flow
32.4M
-
Financing Cash Flow
21.3M
↓ 10.25%

Technicals Summary

Sell

Neutral

Buy

CHINOOK THERAPEUTICS INC is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
CHINOOK THERAPEUTICS INC
CHINOOK THERAPEUTICS INC
17.49%
2.91%
53.56%
38.34%
-45.79%
Moderna, Inc.
Moderna, Inc.
-5.37%
-28.24%
-13.14%
103.02%
578.71%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.12%
-3.55%
9.07%
20.95%
140.97%
Seagen, Inc.
Seagen, Inc.
-2.85%
59.4%
42.61%
21.68%
240.77%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.35%
4.3%
22.83%
15.12%
110.67%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
CHINOOK THERAPEUTICS INC
CHINOOK THERAPEUTICS INC
NA
NA
NA
-3.23
-0.52
-0.23
0.0
6.17
Moderna, Inc.
Moderna, Inc.
11.22
11.22
0.0
-1.83
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.53
26.53
0.41
13.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
CHINOOK THERAPEUTICS INC
CHINOOK THERAPEUTICS INC
Buy
$1.6B
-45.79%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.1B
578.71%
11.22
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
140.97%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.3B
240.77%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.0B
110.67%
26.53
35.4%

Institutional Holdings

  • Samsara BioCapital, LLC

    7.72%

  • BlackRock Inc

    5.91%

  • Deep Track Capital, LP

    4.49%

  • Vanguard Group Inc

    4.26%

  • State Street Corporation

    4.02%

  • Octagon Capital Advisors LP

    3.81%

Corporate Announcements

  • CHINOOK THERAPEUTICS INC Earnings

    CHINOOK THERAPEUTICS INC’s price-to-earnings ratio stands at None

    Read More

Company Information

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.

Organization
CHINOOK THERAPEUTICS INC
Employees
214
CEO
Mr. Eric L. Dobmeier J.D.
Industry
Health Technology

Discover More

FAQs